Tefron 2025: Retail Holds Up, But The Balance Sheet Funds The Transition

Getting To Know The Company

Tefron is not just another apparel manufacturer. It is a seamless underwear, activewear, and athleisure platform built around two very different engines. One is the brands segment, where the company develops and manufactures more complex products for names such as Under Armour and Gymshark, mostly through its own production base in Jordan. The other is the retail segment, where it sells mainly to large North American chains such as Wal-Mart and Target and relies much more heavily on subcontractors in the Far East.

What is working right now is retail. In 2025 the retail segment still generated $180.6 million of revenue and $8.1 million of operating profit, and it even returned to growth in the fourth quarter. What is blocking the story is the brands segment, which should be the value engine of the company. Revenue there fell 39.9% to $56.7 million, while operating profit almost disappeared at just $629 thousand. Once that is paired with the fact that 72% of brands sales are produced in-house, it becomes clear why the weakness in brands hurts much more than an ordinary volume decline.

A superficial read of 2025 can miss two things. The first is that U.S. tariffs were not just a macro headline. They were a direct hit of roughly $3 million to 2025 pre-tax profit, including about $1.5 million in the fourth quarter alone. The second is that 2025 was also a year of heavy investment in a new Jordan facility and in expanding Tefron's own manufacturing base. That means the real question is no longer only whether the company stayed profitable. It is whether 2025 bought Tefron a more efficient 2026 platform, or simply shifted the strain onto the balance sheet.

That matters even at the first screen. Tefron's current market value is roughly NIS 179 million, while the latest daily trading turnover was only about NIS 3.9 thousand. Even if the thesis improves, this remains a very small and very illiquid stock. It still needs several operating and financing milestones to go right.

Four points need to be held from the start:

• First finding: retail is cushioning the year, but brands still determine whether the self-production platform actually earns its keep.
• Second finding: the balance sheet is not broken, but 2025 was a funded bridge year rather than self-financed growth.
• Third finding: the comforting headline of net debt to EBITDA at 0.96 hides the tighter metric, debt-service coverage of only 1.32 against a 1.20 floor.
• Fourth finding: the March 2026 order book says retail is filling the hole, not brands, so 2026 will first be judged on whether brands recover enough volume to re-absorb the fixed-cost base.

Tefron's economic map in 2025:

Events And Triggers

The 2025 story rests on three triggers that need to be read together: U.S. tariffs, the Jordan investment push, and the fact that the fourth quarter already showed retail holding up while brands still had not recovered.

U.S. Tariffs

First trigger: tariffs in the U.S. are already in the numbers, not just in the narrative. The company estimates that the new tariff regime cut 2025 pre-tax profit by about $3 million, of which about $1.5 million hit in the fourth quarter. That is exactly why the retail segment looks tricky to read: revenue is still holding up and even grew in the fourth quarter, but profitability was hit because part of the story is being financed through an added cost burden rather than through pure demand weakness.

At the same time, a possible tariff-refund route opened after the balance-sheet date. On February 20, 2026, the U.S. Supreme Court cancelled part of the tariff regime, and Tefron believes there is a reasonable chance that tariff refunds can eventually be collected. That is a real positive optionality point, but it is still not a clean thesis anchor. Timing and mechanics remain uncertain, and the U.S. administration can still delay or challenge parts of the process.

Expanding Own Production In Jordan

Second trigger: Tefron accelerated in 2025 a move that had already been building in the background, the expansion of its own manufacturing base in Jordan. Non-current assets rose 41.9% to $58.6 million, mainly because of investments in machinery and leasehold improvements tied to expanding own production in Jordan. The investment cap under the financing agreement was lifted from $12 million to $17 million and then later to $21 million. That is not a technical footnote. It is a practical acknowledgment that 2025 required more capital than the original financing framework was built to carry.

Management also states explicitly what comes next: a move into a new building that should consolidate most of the Jordan manufacturing activity during the second quarter of 2026. If that works, it should raise capacity, improve process efficiency, and lower production costs. If it slips or costs more than expected, 2025 will look like a year that consumed cash before the return arrived.

The Signal Already Visible In Q4

Third trigger: the fourth quarter already gave a clear signal about the structure of the story. Group sales fell 13.6% to $54.8 million, operating profit fell 61.5% to $1.1 million, and the company posted a net loss of $661 thousand. But below the surface the split is sharp: brands revenue fell 48% to $14.2 million, while retail revenue actually rose 12.4% to $40.6 million.

What matters here is not just the decline. It is the shape of the decline. In Q4, retail grew because sales to major customers rose about 26%, but unit volume still fell about 4% while average selling price rose 17% because of mix. In other words, even where there is growth, it is not clean volume growth.

Efficiency, Profitability And Competition

Tefron entered 2025 with a brands-demand problem and left it with a fixed-cost absorption problem. That is the key difference between an ordinary sales decline and a decline that hits the very engine that is supposed to justify own production, development, and innovation.

Brands Weakened Exactly Where Tefron Needed Volume Most

The brands segment fell from $94.3 million in 2024 to $56.7 million in 2025. The 2024 rebound simply did not hold. Gross profit in the segment dropped from $21.6 million to $8.4 million, while gross margin fell to 14.9% from 22.9%. Operating profit went from $11.4 million to only $629 thousand.

The core reason is not just lower demand. It is the fact that brands is the segment that relies most heavily on Tefron's own production base. In 2025, about 72% of brands sales were produced in-house, versus only 28% through subcontractors. When brands revenue falls, the hit lands on a fixed-cost layer that retail does not carry with the same intensity.

That connects directly to utilization. Tefron's own production capacity stood at about 23 million units in 2025, but actual output was only about 13 million units, or 56% utilization, down from 65% in 2024. That is not a collapse, but it is more than enough to create margin pressure when the brands engine that should feed the line weakens.

This is also where competition matters. Tefron describes technological advantage, long customer relationships, and advanced production capabilities. But it also states clearly that it has no exclusivity with its customers, and that the relationships are usually governed by standard customer-led framework agreements and short purchase orders without minimum commitments. So the advantage is real, but it does not block a sharp demand reset.

Retail Is Carrying The Story, But At The Cost Of Concentration And Commercial Pressure

The retail segment held up much better, slipping from $199.6 million to $180.6 million while still generating $8.1 million of operating profit. Gross margin fell only slightly, from 22.5% to 22.2%, mainly because two forces pushed in opposite directions: better mix on one side and tariff pressure on the other.

But retail is not just carrying the company. It is also concentrating the risk. In 2025, Wal-Mart represented $65.7 million of revenue, or 27.7% of consolidated sales. Target added another $51.7 million, or 21.8%. A third customer contributed $35.9 million, or 15.2%. The top three customers together account for 64.7% of revenue. That is very heavy concentration, especially in relationships that carry no minimum purchase obligations and no exclusivity.

The yellow flag is not only who the customers are. It is also how the commercial terms work. Payment terms for major customers range from 60 to 120 days, and with Wal-Mart and Target the company uses accelerated payment mechanisms in return for interest, reducing actual payment timing to up to 30 days. That matters because it supports liquidity, but it also means part of the commercial relationship is funded, not simply sold.

The quality of the Q4 retail growth also matters. Revenue there rose 12.4% to $40.6 million, but this was not volume-led growth. Unit volumes were down, average selling price was up, and tariffs were already eroding margins. Retail is therefore holding the business together, but it is not yet solving the question of whether 2026 economics will be cleaner or only less weak.

Cash Flow, Debt And Capital Structure

The right way to read 2025 is through an all-in cash-flexibility lens, meaning how much cash was truly left after the year's actual cash uses. In Tefron's case that is the key discipline, because the company did not roll into a classic debt crisis, but it clearly pulled the transition year through the balance sheet.

The Full Cash Picture

Cash flow from operations came in at $11.0 million. That is not a bad number on its own, but it was simply not enough relative to what followed. Tefron spent $19.9 million on property, plant, equipment, and intangible assets, paid $2.1 million of dividends, and paid out $6.3 million of lease and other contractual repayments. Without new debt, this year would not have ended with higher cash.

Put plainly, Tefron's $11 million of operating cash did not fund a nearly $20 million investment year. It also did not fund the dividend, the lease burden, or the other contractual repayments. The gap was closed with more bank financing. That is not a disaster, because the company still meets its covenants, but it does mean the simple statement that cash ended the year higher can mislead if the funding path is ignored.

There is another important point about the quality of that cash flow. In 2025 receivables fell by $15.4 million because sales were lower, but payables to suppliers also fell by $11.8 million and inventory rose by $3.3 million. So there was no clean working-capital release that repaired the picture. On the contrary, the lower sales base did not translate into a real cash cushion.

The operating working-capital tables make that even clearer:

Add to that the fact that the company recorded a $2.289 million provision for slow-moving inventory in 2025, versus $965 thousand in 2024. Total inventory at year-end stood at $49.7 million, about 31.8% of total assets, and inventory was also flagged as a key audit matter. That is not proof of an inventory crisis, but it is an external signal that inventory has already become heavy enough to demand special attention.

Debt, Covenants, And The Real Headroom

Tefron ended 2025 with $14.5 million of short-term bank credit and $8.5 million of long-term bank debt, against $7.7 million of cash. Net, that is a move from a lightly net-cash position at the end of 2024 to roughly $15.3 million of net bank debt at the end of 2025. At the same time, all company and consolidated-subsidiary assets are pledged to the bank.

This is not a broken balance sheet. The company also had roughly $33 million of unused credit availability derived from its collateral base. But it is also not a balance sheet that should be called comfortable without qualification. The reason is that the metric that matters in the near term is not net debt to EBITDA. It is debt-service coverage.

That is a point the market can miss on first read. Net debt to EBITDA at 0.96 looks very comfortable. But debt-service coverage at 1.32 against a 1.20 floor means that while the company is clearly not near a breach, it is also not sitting on a huge margin if 2026 requires more bridging. So the real 2026 question is not whether Tefron can carry debt. It is whether this debt stays a short bridge rather than becoming a habit.

Forecasts And What Comes Next

Four non-obvious findings frame 2026:

• First finding: the March 2026 order book, including the first quarter, barely changed at the total level, $108.6 million versus $107.3 million at the comparable prior-year date, but the mix shifted even further toward retail.
• Second finding: the brands segment is still soft even on the forward read. The brands order book as of March 25, 2026 stood at only $22.5 million versus $26.4 million at the comparable prior-year point.
• Third finding: the move into the new Jordan facility is supposed to happen in Q2 2026, which means most of the investment has already been booked while most of the operational relief still has to arrive.
• Fourth finding: a tariff-refund scenario could improve the market read, but it does not solve the brands-demand problem and should not substitute for operating proof.

What The 2026 Read Already Shows

Tefron itself warns that backlog is not a full indicator because of the order structure and because of tariff volatility. Even so, the March table gives a useful directional clue about the mix. Retail as of March 25, 2026 stood at $86.1 million versus $80.9 million at the comparable date a year earlier. Brands fell to $22.5 million from $26.4 million.

That chart matters. It does not say Tefron is out of trouble. It says that the gap in brands is currently being offset by retail. That helps near-term revenue, but it is not the same economics. Retail is larger, more concentrated, more tariff-sensitive, and less directly tied to the own-production base through which Tefron is trying to build advantage.

Why 2026 Looks Like A Bridge Year, Not A Breakout Year

Management's 2026 strategy is clear enough: broaden the customer base, deepen Europe, move into the new Jordan facility, diversify subcontractors away from China, and keep investing in newer technology. All of that sounds directionally right. The problem is timing. In 2025 the cash already went out. In 2026 management now has to show that efficiency actually comes back.

That is why 2026 looks like a bridge year. Tefron needs to protect revenue through retail, bring brands back gradually, and absorb the Jordan move without opening another cash hole. If that works, 2027 can look cleaner. If not, the company risks being stuck between a more expensive manufacturing platform and a demand engine that is not returning fast enough.

What Must Happen Over The Next 2 To 4 Quarters

• Brands need to stop falling, and ideally return to a level that supports much better absorption of the own-production base.
• The move into the new Jordan complex needs to translate into real operating efficiency rather than just more spending and transition friction.
• Inventory days and customer days need to stop drifting upward, otherwise even revenue stabilization will remain cash-heavy.
• Debt-service coverage needs to move further away from the floor without relying on another debt-heavy bridge.

Risks

Tefron's risks are not abstract. They sit exactly where the positive thesis also sits.

There is also a risk that does not sit cleanly in the headlines. Customers themselves are aware of the Jordan and regional-security exposure. The company says explicitly that this can affect customer behavior and that it cannot quantify that risk. That matters because Tefron does not need a full disruption for the risk to hurt. It is enough for a large customer to split orders elsewhere geographically or slow joint development.

On the other hand, one near-term market risk does not currently look extreme. Short interest is only 0.28% of float, with SIR at 1.55, below the sector averages of 0.46% and 1.653. That is not proof of strong fundamentals, but it does suggest that the market is not currently building an aggressive short thesis. In Tefron's case, skepticism is showing up more through illiquidity and through the demand for operating proof.

Conclusions

Tefron is not on the brink, but it is also not at a breakout point. Retail is still holding revenue and most of the profit, covenants are still intact, and there is also potential upside from tariff refunds. The central blocker is that the year in which the company invested most heavily in its future platform was also the year in which brands weakened, so the payoff from that investment is not yet visible in the numbers.

Current thesis in one line: Tefron enters 2026 as a retail-driven company funding an industrial transition, not yet as a brands company once again benefiting from its own manufacturing base.

What changed versus 2024 is fairly clear. In 2024 Tefron still combined higher revenue, stronger brands, and an almost clean net bank-debt position. In 2025 the center of gravity shifted. Retail became the shock absorber, brands stopped filling the self-production base, and the balance sheet had to carry the transition year.

The strongest counter-thesis is that the worst is already behind the company: retail stayed profitable, Q4 returned to operating profit, the total early-2026 order book did not shrink, and the new Jordan complex together with potential tariff refunds could make 2026 much better than 2025 leaves it looking. That is a real possibility. But it still depends on several milestones that have not yet been proven.

What can change the market's reading in the short to medium term is a combination of four things: the actual pace of the Jordan move, signs of brands recovery, tangible progress on tariff refunds, and the ability to keep debt-service coverage comfortable without layering on more bridging debt.

Why this matters is simple. With Tefron, the real question is not whether management can tell a coherent strategic story. It can. The real question is whether within the next 2 to 4 quarters the expanded manufacturing platform starts translating back into profit, cash, and wider breathing room. If yes, 2025 will look like a bridge year. If not, it will look like a year in which retail bought the company time, but did not solve the underlying problem.